CPHL Stock Overview
Citi Pharma Limited engages in the manufacture and sale of pharmaceutical, medical chemical, and botanical products in Pakistan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Citi Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨25.05 |
| 52 Week High | PK₨28.35 |
| 52 Week Low | PK₨19.07 |
| Beta | 0.63 |
| 1 Month Change | 7.46% |
| 3 Month Change | 13.61% |
| 1 Year Change | -3.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPHL | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | 2.9% | 4.2% | 1.7% |
| 1Y | -3.8% | 41.7% | 56.5% |
Return vs Industry: CPHL underperformed the PK Pharmaceuticals industry which returned 38.6% over the past year.
Return vs Market: CPHL underperformed the PK Market which returned 58% over the past year.
Price Volatility
| CPHL volatility | |
|---|---|
| CPHL Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in PK Market | 8.1% |
| 10% least volatile stocks in PK Market | 3.5% |
Stable Share Price: CPHL has not had significant price volatility in the past 3 months.
Volatility Over Time: CPHL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 594 | Rizwan Ahmad | www.citipharma.com.pk |
Citi Pharma Limited engages in the manufacture and sale of pharmaceutical, medical chemical, and botanical products in Pakistan. The company was founded in 1990 and is headquartered in Lahore, Pakistan.
Citi Pharma Limited Fundamentals Summary
| CPHL fundamental statistics | |
|---|---|
| Market cap | PK₨5.59b |
| Earnings (TTM) | PK₨657.98m |
| Revenue (TTM) | PK₨12.40b |
8.7x
P/E Ratio0.5x
P/S RatioIs CPHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPHL income statement (TTM) | |
|---|---|
| Revenue | PK₨12.40b |
| Cost of Revenue | PK₨10.90b |
| Gross Profit | PK₨1.50b |
| Other Expenses | PK₨839.53m |
| Earnings | PK₨657.98m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.88 |
| Gross Margin | 12.08% |
| Net Profit Margin | 5.31% |
| Debt/Equity Ratio | 34.1% |
How did CPHL perform over the long term?
See historical performance and comparison